1 Consider treatment response and tolerability when selecting the maintenance dosage 1 Recommended maintenance doses: Adult CV risk reduction: 1.7 mg or 2.4 mg (recommended) Adult weight reduction: 1.7 mg, 2.4 mg (recommended), or 7.2 mg (when additional weight reduction is clinically indicated) Adolescent weight reduction: 1.7 mg or 2.4 mg (recommended) CV, cardiovascular
By addressing the root causes of weight gain and building healthy, lasting habits, we help you maintain results and prevent rebound weight.
Among the seleno-GPxs, GPx2 and GPx4 have the highest priority for selenium utilization, suggesting the important roles played by them in maintaining the cellular antioxidant defense mechanisms [8, 25]
Adverse Reactions (3% and Greater than Placebo) in WEGOVY-Treated Pediatric Patients Aged 12 Years and Older with Obesity for Weight Reduction Adverse Reactions in Clinical Trials in Adults with MASH The safety of WEGOVY was evaluated in a randomized, double-blind, placebo-controlled trial (Study 8) that included 1,195 adult patients with MASH, including 800 patients who were exposed to WEGOVY for a median of 95.3 weeks and 395 patients who were exposed to placebo for a median of 83.1 weeks [see Clinical Studies (14.4)]
Limit high-fat and high-sugar foods that accelerate intestinal transit
Many patients report changes in food preferences, reduced cravings for sweets, and less interest in eating larger portions within the first 24 weeks
